Nuzenio

Hybrozyme

Hybrozyme news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 7 latest news signals 7 publisher sources 100/100 entity strength

Latest news

Alteogen returns to profit as Keytruda SC sales and platform deals surge - CHOSUNBIZ - ChosunbizChosunbiz · Fri, 07 Aug 2026 02:00:00 GMTAlteogen Signs Up to $365 Million Hybrozyme Licensing Deal for Subcutaneous Biologic - BioPharma APACBioPharma APAC · Fri, 07 Aug 2026 01:06:22 GMTAlteogen signs $365m Hybrozyme licensing deal with pharma company - Pharmaceutical TechnologyPharmaceutical Technology · Thu, 06 Aug 2026 17:23:32 GMTAlteogen signs up to $365 million licensing deal for Hybrozyme drug delivery technology - Indian Pharma PostIndian Pharma Post · Thu, 06 Aug 2026 13:00:00 GMTKorea's Alteogen inks $365 M deal for development and commercialisation of Hybrozyme™-enabled subcutaneous biologic product - BioSpectrum AsiaBioSpectrum Asia · Thu, 06 Aug 2026 12:06:10 GMTAlteogen Licenses Subcutaneous Platform to Undisclosed Global Pharma Company in Deal Worth Up to $365 Million - BioPharm InternationalBioPharm International · Wed, 05 Aug 2026 19:10:58 GMTAlteogen Announces Exclusive License Agreement with a Global Pharmaceutical Company for the Development and Commercialization of a Hybrozyme™-Enabled Subcutaneous Biologic Product - Yahoo FinanceYahoo Finance · Wed, 05 Aug 2026 12:00:00 GMT

Timeline

Fri, 07 Aug 2026 02:00:00 GMTAlteogen returns to profit as Keytruda SC sales and platform deals surge - CHOSUNBIZ - Chosunbiz
Fri, 07 Aug 2026 01:06:22 GMTAlteogen Signs Up to $365 Million Hybrozyme Licensing Deal for Subcutaneous Biologic - BioPharma APAC
Thu, 06 Aug 2026 17:23:32 GMTAlteogen signs $365m Hybrozyme licensing deal with pharma company - Pharmaceutical Technology
Thu, 06 Aug 2026 13:00:00 GMTAlteogen signs up to $365 million licensing deal for Hybrozyme drug delivery technology - Indian Pharma Post
Thu, 06 Aug 2026 12:06:10 GMTKorea's Alteogen inks $365 M deal for development and commercialisation of Hybrozyme™-enabled subcutaneous biologic product - BioSpectrum Asia
Wed, 05 Aug 2026 19:10:58 GMTAlteogen Licenses Subcutaneous Platform to Undisclosed Global Pharma Company in Deal Worth Up to $365 Million - BioPharm International

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Hybrozyme.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

7 distinct publisher/source names are currently connected to this entity page.